NCT00002565 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00002565/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
cytarabine [clinicaltrials_resource:365f8fcdfa69d1c55e8c02dc0fbdea6f]bleomycin sulfate [clinicaltrials_resource:582a91f5950e82ee3b8a1101a824db3c]idarubicin [clinicaltrials_resource:65af7246fc9709f0aaae35aceb4d0e23]cisplatin [clinicaltrials_resource:69455b38265d55b661d0bfa786c83abe]vincristine sulfate [clinicaltrials_resource:6ca167850a60c238ac072f414e497251]etoposide [clinicaltrials_resource:7cb6076e8355e089ce983cf1f80658d9]ifosfamide [clinicaltrials_resource:a371eedecd1223a82190c7976312ee4f]methylprednisolone [clinicaltrials_resource:cce0633e190a7cbb1d72ffaadc008a38]mesna [clinicaltrials_resource:ebce04cfe271678c597e4f43c53f4e07]mitoxantrone hydrochloride [clinicaltrials_resource:ef7dc56be5bd26a6ea4c5656a35a1044]cyclophosphamide [clinicaltrials_resource:fe7aa7a8c520804ddb380e7e28d00231]Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma [clinicaltrials:NCT00002565]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00002565 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00002565/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00002565/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
Sequential 4-, 5-, and 3-Drug ...... ide, mitoxantrone, etoposide).
identifier
clinicaltrials_resource:NCT00002565/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00002565 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00002565 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en